logo

For the Inventor, By the Inventor

Guilford, CT, United States of America

Timothy M Caldwell

This inventor holds 8 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Neurogen Corporation. Active years: 2005-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Timothy M Caldwell. Retrieved from https://idiyas.com/inventor/timothy-m-caldwell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 50.0

 

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 56(Granted Patents)


Location History:

  • Branford, CT (US) (2005 - 2006)
  • Guilford, CT (US) (2007 - 2011)

Company Filing History:

goldMedal8 out of 305 
 
Neurogen Corporation
 patents

Years Active: 2005-2011

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents
1. 7935702 - Substituted biaryl quinolin-4-ylamine analogues (2011-05-03),
2. 7851474 - Dipiperazinyl ketones and related analogues (2010-12-14),
3. 7488740 - Substituted quinolin-4-ylamine analogues (2009-02-10),
4. 7432275 - Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators (2008-10-07),
5. 7304059 - Substituted quinazolin-4-ylamine analogues (2007-12-04),
6. 7241765 - Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues (2007-07-10),
7. 7074799 - Substituted quinazolin-4-ylamine analogues (2006-07-11),
8. 6953801 - Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues (2005-10-11),

Title: Innovations and Contributions of Timothy M Caldwell

Introduction

Timothy M Caldwell is a notable inventor based in Guilford, CT (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 8 patents to his name, Caldwell has made strides in developing compounds that have the potential to treat various medical conditions.

Latest Patents

Caldwell's latest patents include "Substituted biaryl quinolin-4-ylamine analogues," which are designed to modulate specific receptor activity both in vivo and in vitro. These compounds are particularly useful in treating conditions associated with pathological receptor activation in humans, domesticated companion animals, and livestock animals. Additionally, he has developed "Dipiperazinyl ketones and related analogues," which can modulate ligand binding to histamine H3 receptors. These compounds also hold promise for treating a variety of disorders in both humans and animals.

Career Highlights

Caldwell is currently associated with Neurogen Corporation, where he continues to innovate and contribute to the pharmaceutical industry. His work focuses on creating effective therapeutic methods and pharmaceutical compositions that can improve health outcomes.

Collaborations

Caldwell has collaborated with notable colleagues such as Rajagopal Bakthavatchalam and Kevin J Hodgetts, enhancing the research and development efforts at Neurogen Corporation.

Conclusion

Timothy M Caldwell's work exemplifies the impact of innovative thinking in the pharmaceutical field. His patents and ongoing research contribute significantly to advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…